Novel Anticancer Strategies
Novel Anticancer Strategies reviews important findings and updates within the cancer therapy field, of great interest to those in academic research studying the development and validation of novel anticancer approaches. The Editor invited preeminent specialists to contribute to original and review a...
Saved in:
| Other Authors: | |
|---|---|
| Format: | Electronic Book Chapter |
| Language: | English |
| Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2023
|
| Subjects: | |
| Online Access: | DOAB: download the publication DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_98932 | ||
| 005 | 20230405 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20230405s2023 xx |||||o ||| 0|eng d | ||
| 020 | |a books978-3-0365-7030-3 | ||
| 020 | |a 9783036570310 | ||
| 020 | |a 9783036570303 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.3390/books978-3-0365-7030-3 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a M |2 bicssc | |
| 072 | 7 | |a MJCL |2 bicssc | |
| 100 | 1 | |a Bousbaa, Hassan |4 edt | |
| 700 | 1 | |a Bousbaa, Hassan |4 oth | |
| 245 | 1 | 0 | |a Novel Anticancer Strategies |
| 260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2023 | ||
| 300 | |a 1 electronic resource (396 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a Novel Anticancer Strategies reviews important findings and updates within the cancer therapy field, of great interest to those in academic research studying the development and validation of novel anticancer approaches. The Editor invited preeminent specialists to contribute to original and review articles devoted to key areas of major progress and expectations. Key features: Nanoparticle-based drug delivery in cancer therapy; Extracellular vesicles for anticancer drug delivery; Peptide-based drug conjugates; Cancer stem cells as a valuable target to eradicate tumor relapse; Spheroids in preclinical model for cancer research; and cancer immunotherapy. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine |2 bicssc | |
| 650 | 7 | |a Oncology |2 bicssc | |
| 653 | |a tumor-homing extracellular vesicles | ||
| 653 | |a pH-sensitive extracellular vesicles | ||
| 653 | |a doxorubicin | ||
| 653 | |a tumor therapy | ||
| 653 | |a pancreatic cancer | ||
| 653 | |a targeted tumor therapy | ||
| 653 | |a homing peptide | ||
| 653 | |a antitumor peptide conjugates | ||
| 653 | |a daunomycin | ||
| 653 | |a oxime linkage | ||
| 653 | |a combinatorial immunotherapy | ||
| 653 | |a cytotoxics | ||
| 653 | |a biomarkers | ||
| 653 | |a precision medicine | ||
| 653 | |a immunotherapy | ||
| 653 | |a anti-PD-L1 | ||
| 653 | |a ionizing irradiation | ||
| 653 | |a pharmacokinetics | ||
| 653 | |a tumor-immune interaction | ||
| 653 | |a global sensitivity | ||
| 653 | |a immuno-oncology | ||
| 653 | |a mathematical modeling | ||
| 653 | |a glycol chitosan nanoparticle | ||
| 653 | |a high-intensity focused ultrasound | ||
| 653 | |a deep tumor penetration | ||
| 653 | |a dense ECM | ||
| 653 | |a cancer treatment | ||
| 653 | |a prostate cancer | ||
| 653 | |a gastrin-releasing peptide receptor | ||
| 653 | |a RM26 | ||
| 653 | |a albumin-binding domain | ||
| 653 | |a targeted therapy | ||
| 653 | |a gastrin-releasing peptide receptors (GRPR) antagonist | ||
| 653 | |a cervical cancer | ||
| 653 | |a tetraarsenic hexoxide | ||
| 653 | |a patient-derived xenograft | ||
| 653 | |a autophagy | ||
| 653 | |a cisplatin | ||
| 653 | |a fenbendazole | ||
| 653 | |a micelle solubilization | ||
| 653 | |a Soluplus® polymeric micelles | ||
| 653 | |a toxicity test | ||
| 653 | |a sonoporation | ||
| 653 | |a microbubbles | ||
| 653 | |a ultrasound | ||
| 653 | |a intracellular signaling | ||
| 653 | |a phosphorylation | ||
| 653 | |a ultrasound contrast agents | ||
| 653 | |a drug delivery | ||
| 653 | |a cellular stress | ||
| 653 | |a tumour microenvironment | ||
| 653 | |a cancer stem cells | ||
| 653 | |a extracellular vesicles | ||
| 653 | |a drug delivery systems | ||
| 653 | |a liposomes | ||
| 653 | |a immunoliposomes | ||
| 653 | |a antisense oligonucleotides | ||
| 653 | |a 3D cultures | ||
| 653 | |a tumor microenvironment | ||
| 653 | |a tumor spheroids | ||
| 653 | |a efficacy analysis | ||
| 653 | |a drug resistance | ||
| 653 | |a cancer therapy | ||
| 653 | |a glioblastoma | ||
| 653 | |a receptor tyrosine kinases | ||
| 653 | |a epidermal growth factor receptor | ||
| 653 | |a small molecule inhibitors | ||
| 653 | |a nanoformulations | ||
| 653 | |a breast cancer | ||
| 653 | |a micelles | ||
| 653 | |a dendrimers | ||
| 653 | |a anticancer drugs | ||
| 653 | |a platinum drug | ||
| 653 | |a methotrexate | ||
| 653 | |a lung metastasis | ||
| 653 | |a liver metastasis | ||
| 653 | |a cancer treatments and progression biomarkers | ||
| 653 | |a mesoporous silica nanoparticles | ||
| 653 | |a controlled release | ||
| 653 | |a anticancer natural prodrugs | ||
| 653 | |a natural products | ||
| 653 | |a cancer targeting | ||
| 653 | |a nanoformulations/nanomedicine applications | ||
| 653 | |a n/a | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/6985 |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/98932 |7 0 |z DOAB: description of the publication |